Nothing Special   »   [go: up one dir, main page]

WO2004048541A3 - Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants - Google Patents

Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants Download PDF

Info

Publication number
WO2004048541A3
WO2004048541A3 PCT/US2003/037548 US0337548W WO2004048541A3 WO 2004048541 A3 WO2004048541 A3 WO 2004048541A3 US 0337548 W US0337548 W US 0337548W WO 2004048541 A3 WO2004048541 A3 WO 2004048541A3
Authority
WO
WIPO (PCT)
Prior art keywords
pathway
methods
cct6s
modifiers
cct6
Prior art date
Application number
PCT/US2003/037548
Other languages
English (en)
Other versions
WO2004048541A2 (fr
Inventor
Albert K Tai
Chunyan Song
Michael Martin Ollmann
Lucile A Gillett
Kim Lickteig
Original Assignee
Exelixis Inc
Albert K Tai
Chunyan Song
Michael Martin Ollmann
Lucile A Gillett
Kim Lickteig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc, Albert K Tai, Chunyan Song, Michael Martin Ollmann, Lucile A Gillett, Kim Lickteig filed Critical Exelixis Inc
Priority to EP03789986A priority Critical patent/EP1578945A4/fr
Priority to JP2004555682A priority patent/JP4646631B2/ja
Priority to CA002506686A priority patent/CA2506686A1/fr
Priority to AU2003294501A priority patent/AU2003294501B2/en
Publication of WO2004048541A2 publication Critical patent/WO2004048541A2/fr
Publication of WO2004048541A3 publication Critical patent/WO2004048541A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Des gènes CCT6 humains sont identifiés comme modulateurs de la voie RB et sont, en conséquence, des cibles thérapeutiques pour des troubles associés à une fonction RB défectueuse. L'invention concerne des procédés d'identification de modulateurs de RB, comprenant la sélection d'agents modulant l'activité de CCT6.
PCT/US2003/037548 2002-11-25 2003-11-24 Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants WO2004048541A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP03789986A EP1578945A4 (fr) 2002-11-25 2003-11-24 Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants
JP2004555682A JP4646631B2 (ja) 2002-11-25 2003-11-24 ＲＢ経路のモディファイヤーとしてのＣＣＴ６ｓおよび使用方法
CA002506686A CA2506686A1 (fr) 2002-11-25 2003-11-24 Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants
AU2003294501A AU2003294501B2 (en) 2002-11-25 2003-11-24 CCT6S as modifiers of the RB pathway and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42887202P 2002-11-25 2002-11-25
US60/428,872 2002-11-25

Publications (2)

Publication Number Publication Date
WO2004048541A2 WO2004048541A2 (fr) 2004-06-10
WO2004048541A3 true WO2004048541A3 (fr) 2005-08-18

Family

ID=32393472

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2003/037548 WO2004048541A2 (fr) 2002-11-25 2003-11-24 Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants
PCT/US2003/037538 WO2004048536A2 (fr) 2002-11-25 2003-11-24 Rhebs utilises comme modificateurs de la voie rb et methodes d'utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2003/037538 WO2004048536A2 (fr) 2002-11-25 2003-11-24 Rhebs utilises comme modificateurs de la voie rb et methodes d'utilisation

Country Status (5)

Country Link
EP (1) EP1578945A4 (fr)
JP (1) JP4646631B2 (fr)
AU (2) AU2003294501B2 (fr)
CA (1) CA2506686A1 (fr)
WO (2) WO2004048541A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5646990B2 (ja) 2007-04-23 2014-12-24 ストワーズ インスティテュート フォー メディカル リサーチ 幹細胞自己複製のための方法及び組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6071715A (en) * 1993-08-12 2000-06-06 Board Of Regents, The University Of Texas System Nucleic acids encoding novel proteins which bind to retinoblastoma protein
GB9608937D0 (en) * 1996-04-29 1996-07-03 Cancer Res Campaign Tech Screening methods for therapeutics and peptides used in the screen
EP1054969A2 (fr) * 1998-02-12 2000-11-29 Curagen Corporation Complexes proteiques de retinoblastome et proteines interagissant avec le retinoblastome

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LIN ET AL.: "Analysis of mutationally altered forms of the Cct6 subunit of the Chaperonin from saccharomyces cerevisiae", GENETICS, vol. 147, December 1997 (1997-12-01), pages 1609 - 1633, XP008049764 *
SCHILLER E. ET AL.: "Brain t-complex polypeptide 1 (TCP-1) related to its natural substrate B1 tubulin is decreased in Alzheimer's disease", LIFE SCIENCES, vol. 69, 2001, pages 263 - 270, XP002988099 *
See also references of EP1578945A4 *

Also Published As

Publication number Publication date
JP4646631B2 (ja) 2011-03-09
EP1578945A4 (fr) 2006-09-27
CA2506686A1 (fr) 2004-06-10
WO2004048536A3 (fr) 2004-08-19
AU2003294501A1 (en) 2004-06-18
JP2006507005A (ja) 2006-03-02
AU2003294499A1 (en) 2004-06-18
EP1578945A2 (fr) 2005-09-28
AU2003294501B2 (en) 2010-05-13
WO2004048541A2 (fr) 2004-06-10
WO2004048536A2 (fr) 2004-06-10
AU2003294499A8 (en) 2004-06-18

Similar Documents

Publication Publication Date Title
WO2003083047A3 (fr) Genes mp53 en tant que modificateurs de la voie des proteines p53 et methodes d'utilisation
WO2002099047A3 (fr) Genes proml en tant que modificateurs de la voie p53 et procedes d'utilisation associes
WO2002099074A3 (fr) Slc7s utilises en tant que modificateurs de la voie p53 et procedes d'utilisation correspondants
WO2003014301A3 (fr) Hprp4 en tant que modificateurs de la voie de passage p53 leurs et methodes d'utilisation
WO2005016287A3 (fr) Prkwnk utilises en tant que modificateurs de la voie rac et methodes d'utilisation associees
WO2003051905A3 (fr) Taojik utilises en tant que modificateurs de la voie beta-catenine et procedes d'utilisation associes
WO2002099043A8 (fr) P5crs identifies comme des modificateurs de la voie p53 et procedes d'utilisation
WO2004024882A3 (fr) Flj20647 utilise en tant que modificateur de la voie p21 et procedes d'utilisation associes
WO2004013309A3 (fr) Papss comme modificateurs de la voie d'axin et procédés d'utilisation
EP1438432A4 (fr) Lrrcaps en tant que modificateurs de la voie de passage p53 et leurs procedes d'utilisation
WO2004014301A3 (fr) Genes psmc utilises comme modificateurs du trajet retiniblastome (rb) et techniques d'utilisation
WO2004005483A3 (fr) Adcy3s modificateurs de la voie p21 et methodes d'utilisation
WO2004015071A3 (fr) Genes csnk1gs utilises en tant que modificateurs de la voie p21 et procede d'utilisation associe
WO2004048541A3 (fr) Cct6 utilises comme modificateurs de la voie rb, et procedes d'utilisation correspondants
WO2004048538A3 (fr) Caseine kinases modifiant la voie rac et leurs procedes d'utilisation
WO2005017123A3 (fr) Mptens utilises comme modificateurs de la voie pten et procedes d'utilisation
WO2004005486A3 (fr) Genes mp21 utilises comme modificateurs de la voie p21 et leurs procedes d'utilisation
WO2004061123A3 (fr) Mbcat servant de modificateurs de la voie de beta-catenine et leurs procedes d'utilisation
WO2003074725A3 (fr) Mbcat comme modificateurs du mecanisme d'action de la $g(b)-catenine et procedes d'utilisation correspondants
WO2004083389A3 (fr) Genes mbcat utilises comme modificateurs de la voie de la beta-catenine et techniques d'utilisation
WO2003074677A3 (fr) Mchk comme modulateurs du mecanisme d'action de chk et procedes d'utilisation
WO2003074673A3 (fr) Lgals tenant lieu de modificateurs de la voie de chk et leurs procedes d'utilisation
WO2003052068A3 (fr) Genes mbcat agissant comme modificateurs du mecanisme d'action de la beta-catenine et methodes d'utilisation
WO2004104168A3 (fr) Mrb utilises comme modificateurs de la voie des rb et procedes d'utilisation correspondants
WO2004067722A3 (fr) Genes facl utilises comme modificateurs de la voie du retinoblastome (rb) et technique d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003294501

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003789986

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2506686

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004555682

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003789986

Country of ref document: EP